Delcath Q4 revenue rises 37%, beats estimates

Overview

• Interventional oncology firm's Q4 revenue rose, beating analyst expectations

• Company reported Q4 net loss but achieved positive adjusted EBITDA

• Company repurchased 628,572 shares for $6 mln under buyback program

Outlook

• Company expects 2026 revenue of at least $100 mln, driven by HEPZATO KIT volume growth

• Delcath anticipates gross margins between 84% and 87% for fiscal year 2026

• Company aims for accelerated adoption through site activations and commercial expansion

Result Drivers

• HEPZATO GROWTH - 140% increase in HEPZATO procedure volume compared to 2024 drove revenue growth

• CLINICAL TRIAL RESULTS - Positive results from CHOPIN trial and other studies increased awareness and demand

• EXPANDED CAPACITY - 28 active centers contributed to increased procedure volume and revenue

Company press release: ID:nBw5M0s78a

Key Details

Analyst Coverage

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 7 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

• The average consensus recommendation for the medical equipment, supplies & distribution peer group is "buy"

• Wall Street's median 12-month price target for Delcath Systems Inc is $22.00, about 115.5% above its February 25 closing price of $10.21

• The stock recently traded at 41 times the next 12-month earnings vs. a P/E of 26 three months ago

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.